{"id":45608,"date":"2026-04-08T02:35:20","date_gmt":"2026-04-08T02:35:20","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/45608\/"},"modified":"2026-04-08T02:35:20","modified_gmt":"2026-04-08T02:35:20","slug":"novartis-excellergy-deal-highlights-push-into-allergy-biologics-and-returns-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/45608\/","title":{"rendered":"Novartis Excellergy Deal Highlights Push Into Allergy Biologics And Returns"},"content":{"rendered":"\n

Make better investment decisions<\/a> with Simply Wall St’s easy, visual tools that give you a competitive edge.<\/p>\n

Novartis (SWX:NOVN) has agreed to acquire Excellergy, a biotech focused on biologic treatments that target immunoglobulin E for allergy driven diseases.<\/p>\n

The deal brings Excellergy\u2019s biologic platforms and pipeline candidates into Novartis, expanding its reach in specialty pharmaceuticals aimed at unmet allergy needs.<\/p>\n

The acquisition is intended to strengthen Novartis\u2019 capabilities in biologic therapies for patients with allergy related conditions.<\/p>\n

For investors tracking SWX:NOVN, this move comes with the shares at around CHF122.9 and a 13.3% return year to date. The stock has gained 30.8% over the past year and 94.3% over five years, during a period in which Novartis has remained a key name in large cap pharmaceuticals.<\/p>\n

The Excellergy purchase adds a fresh angle to Novartis\u2019 existing portfolio, particularly in allergy driven biologics where patient needs remain significant. Investors may want to watch how quickly Novartis integrates Excellergy\u2019s technology and how the new assets progress through development and potential approvals.<\/p>\n

Stay updated on the most important news stories for Novartis<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novartis.<\/p>\n

\"SWX:NOVN<\/a> SWX:NOVN Earnings & Revenue Growth as at Apr 2026 <\/p>\n

\ud83d\udcf0 Beyond the headline: 1 risk and 5 things going right for Novartis that every investor should see.<\/a><\/p>\n

This Excellergy deal gives you a clearer view of where Novartis wants to deepen its focus in allergy care. By bringing in early stage biologic platforms that target immunoglobulin E, Novartis is adding another set of tools alongside existing respiratory and immunology treatments used for chronic conditions. The up to US$2b price tag suggests management sees meaningful scientific and commercial potential. It also concentrates more capital in a space where success will depend on clinical outcomes and regulatory approvals that are still ahead.<\/p>\n

The acquisition lines up with Novartis’ emphasis on advanced therapies such as biologics and supports the idea of a broad, research driven portfolio across immunology and allergy conditions.<\/p>\n

Committing up to US$2b to an early stage biotech adds execution risk if key programs underperform in trials, which could challenge expectations for steady earnings and margin trends.<\/p>\n

The Excellergy pipeline is not explicitly referenced in existing narratives, so timelines, potential indications and competitive positioning for these assets may not yet be reflected in current expectations.<\/p>\n

Story Continues <\/p>\n

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novartis<\/a> to help decide what it’s worth to you.<\/p>\n

\u26a0\ufe0f Integration and development risk if Excellergy’s programs face clinical setbacks or safety issues, especially with competitors like Roche, Sanofi and AstraZeneca also active in allergy and immunology.<\/p>\n

\u26a0\ufe0f Higher R&D and acquisition spending could weigh on profitability if returns from the Excellergy assets take longer than expected or remain limited to narrow indications.<\/p>\n

\ud83c\udf81 The acquisition could broaden Novartis’ allergy focused biologic offerings, supporting long term demand in diseases where treatment options are still limited.<\/p>\n

\ud83c\udf81 A stronger presence in IgE targeted therapies may help Novartis compete more directly in high value allergy segments where peers already have established biologic brands.<\/p>\n

From here, focus on how Novartis outlines development milestones for Excellergy’s candidates, including trial starts, data readouts and regulatory filings. Any updates on how the company plans to combine Excellergy platforms with its existing immunology and respiratory portfolio will also be important for judging future commercial potential. Investors may also want to track how this added investment sits alongside recent earnings, where revenue and net profit were slightly lower year on year, and how analysts interpret the risk and reward trade off in their future ratings and commentary.<\/p>\n

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novartis, head to the community page for Novartis<\/a> to never miss an update on the top community narratives.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVN.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…\n","protected":false},"author":2,"featured_media":18088,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[3264,24986,23164,206],"class_list":["post-45608","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-acquisition","tag-biologic-treatments","tag-excellergy","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116366758598694543","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/45608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=45608"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/45608\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18088"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=45608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=45608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=45608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}